235 related articles for article (PubMed ID: 7720507)
1. [Assay of DNA content and estrogen receptor status in human breast cancer].
Chen GJ; Shao YF; Shan Y
Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):461-4. PubMed ID: 7720507
[TBL] [Abstract][Full Text] [Related]
2. [Study of DNA content using a flow cytometry method and steroid hormone receptors in breast cancer].
Zubrikhina GN; Kuz'mina EV; Bassalyk LS; Murav'eva NI
Vopr Onkol; 1989; 35(10):1179-86. PubMed ID: 2596061
[TBL] [Abstract][Full Text] [Related]
3. Ploidy, proliferative activity and estrogen receptor content in human breast cancer.
Raber MN; Barlogie B; Latreille J; Bedrossian C; Fritsche H; Blumenschein G
Cytometry; 1982 Jul; 3(1):36-41. PubMed ID: 7117052
[TBL] [Abstract][Full Text] [Related]
4. [Male breast cancer. Histochemical and flow cytometry analysis of 6 cases].
Galasso MG; Galia A; Gazzano G; Cosentino A; Castorina S
Pathologica; 1995 Oct; 87(5):503-5. PubMed ID: 8868175
[TBL] [Abstract][Full Text] [Related]
5. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1.
Masood S; Bui MM; Lu L
Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
[TBL] [Abstract][Full Text] [Related]
9. EGF-R expression in ductal breast cancer: proliferation and prognostic implications.
Bucci B; D'Agnano I; Botti C; Mottolese M; Carico E; Zupi G; Vecchione A
Anticancer Res; 1997; 17(1B):769-74. PubMed ID: 9066618
[TBL] [Abstract][Full Text] [Related]
10. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.
Kute TE; Muss HB; Anderson D; Crumb K; Miller B; Burns D; Dube LA
Cancer Res; 1981 Sep; 41(9 Pt 1):3524-9. PubMed ID: 7020931
[TBL] [Abstract][Full Text] [Related]
11. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
12. [The objective comparison of nuclear DNA content with nuclear grade in breast cancer].
Yamamoto N
Nihon Geka Gakkai Zasshi; 1995 Apr; 96(4):236-44. PubMed ID: 7753019
[TBL] [Abstract][Full Text] [Related]
13. DNA proliferative index as a marker in Iraqi aneuploid mammary carcinoma.
al-Alwan NA
East Mediterr Health J; 2000; 6(5-6):1062-72. PubMed ID: 12197329
[TBL] [Abstract][Full Text] [Related]
14. Biological indicators of aggressiveness in T1 ductal invasive breast cancer.
Bucci B; Carico E; Rinaldi A; Froio F; Puce YM; D'Agnano I; Vecchione A; Brunetti E
Anticancer Res; 2001; 21(4B):2949-55. PubMed ID: 11712792
[TBL] [Abstract][Full Text] [Related]
15. Image and flow cytometric analysis of DNA content in breast cancer. Relation to estrogen receptor content and lymph node involvement.
Cornelisse CJ; de Koning HR; Moolenaar AJ; van de Velde CJ; Ploem JS
Anal Quant Cytol; 1984 Mar; 6(1):9-18. PubMed ID: 6732072
[TBL] [Abstract][Full Text] [Related]
16. [Flow cytometry-pathology combined study of breast cancer].
Yu ZY; Yu JM; Wu TH; Zhuo PY; Wang SF; Li M; Zhang X; Lü BY; Liu YB
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):420-2. PubMed ID: 16188128
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of cellular DNA ploidy level of the breast cancer].
Li JY
Zhonghua Wai Ke Za Zhi; 1992 Jan; 30(1):35-7, 63. PubMed ID: 1499424
[TBL] [Abstract][Full Text] [Related]
18. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
Kurbel S
Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
[TBL] [Abstract][Full Text] [Related]
19. Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples.
Leers MP; Nap M
Breast J; 2001; 7(4):249-59. PubMed ID: 11678803
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
